The World Health Organization (WHO) has enlisted three types of Bangladeshi vaccine candidate Bancovid produced by Globe Biotech Limited for pre-clinical trial.
It included the three types -- D614G variant LNP-encapsulated mRNA, DNA plasmid vaccine and Adenovirus Type 5 Vector -– in the draft landscape of COVID-19 candidate vaccines, according to WHO website.
On August 12 last, Dr Asif Mahmood, the head of Globe Biotech’s Research and Development department, said they are hopeful about bringing the vaccine in the market in December next.
Meanwhile, Bancovid, the first D614G variant mRNA-based vaccine candidate against Sars-CoV-2 developed by the Bangladeshi pharmaceutical company, elicits neutralising antibody and balanced cellular immune response, according to US medical journal bioRxiv.
Globe Biotech has joined the global race to develop a coronavirus vaccine in the country as the first company of Bangladesh.
The animal trials of its vaccine have already been completed.